Edgewise Therapeutics, Inc. (EWTX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Edgewise Therapeutics said it will provide a near-term disclosure in December on the CIRRUS study (across 7,500) with a subsequent update in H1 2026, signaling important clinical-readout timing for investors. Management highlighted that the HCM market for mavacamten now has a run rate north of $1 billion, but uptake remains concentrated in centers of excellence due to echo/REMS/safety requirements and limited community cardiologist access, while noting additional agents entering the space could expand overall market opportunity.

Analysis

Market structure: The disclosure cycle for Edgewise (EWTX) and the public confirmation that mavacamten (Camzyos) is now a >$1B run-rate product crystallizes a large HCM end-market where winners will be drugs that reduce REMS/echo burdens and enable community cardiology uptake. Short-term winners: developers with simpler safety/monitoring profiles and diagnostics vendors that expand echo capacity; losers: center-of-excellence–dependent pathways and companies that monetize REMS complexity. Pricing power will soften if multiple entrants demonstrate equivalent efficacy, pushing competition toward convenience and payer-managed formularies.

Risk assessment: Immediate risk is binary—December CIRRUS disclosure (days) can swing EWTX >30–50% on headline efficacy/safety; medium-term (H1 2026) follow-up disclosures can re-rate adoption curves; long-term (3–5 years) the revenue story depends on payer coverage, guideline adoption, and echo access. Tail risks include an adverse safety signal triggering expanded REMS or class warnings, and payer refusal to reimburse without clear community-care economics; hidden dependencies are echo throughput, cardiologist training, and prior-authorization workflows.

Trade implications: Tactical opportunity exists around the December data: a small, hedged long in EWTX to capture positive surprise, transitioning to longer-dated exposure if H1 2026 disclosures validate community uptake. Pair trades: long EWTX versus modest short exposure to BMY (Camzyos owner) can isolate perception of incremental share shift; options: buy defined-cost call spreads ahead of the release and sell premium if implied vol spikes post-data. Sector rotation: overweight specialty biotech (names with simplified monitoring claims) and underweight providers whose revenue depends on high-margin echo/REMS services.

Contrarian angles: Consensus may overestimate speed-to-revenue—positive efficacy alone won't guarantee uptake unless monitoring/reimbursement barriers are demonstrably lower, so immediate rallies can be overdone. Conversely, the market may underprice a product that materially reduces monitoring (fast community adoption), producing multi-bagger upside over 18–36 months. Historical parallels: initial PCSK9 and SGLT2 adoption where guideline/payer shifts lagged clinical evidence; unintended consequences include payer-mandated step edits that entrench incumbents despite superior convenience claims.

Key Decisions for Investors

• Establish a 2% portfolio long position in EWTX ahead of the December CIRRUS disclosure (enter 5–10 trading days prior) and cap downside with a protective hedge: buy a 3–6 month 30% OTM put sized to limit downside to ~50% of the equity notional.
• If December data meet the primary endpoint (p<0.05) and show materially simpler monitoring (no increased LVEF events), increase EWTX exposure to 4–6% of portfolio within 5 trading days and add Dec 2026 LEAP calls to capture 18–36 month adoption (size remaining exposure to no more than 50% of total biotech allocation).
• Execute a small pair hedge: short 0.25–0.5% portfolio of BMY to neutralize macro/market beta and isolate HCM share rotation risk while maintaining directional EWTX upside; close the BMY hedge if EWTX safety profile is neutral and payers signal coverage.
• Use defined-risk option spreads if implied volatility rises: buy a 6-month near-the-money call spread (width ~30–40% of current price) sized to 1–2% portfolio to capture upside while limiting premium; if implied vol collapses post-data, consider selling a higher-strike call spread to finance further upside exposure.
• Hard stop triggers: cut EWTX exposure to <0.5% within 1–2 trading days if the December disclosure shows failure on primary endpoint or any new safety signal (LVEF decline, REMS expansion); re-evaluate only after H1 2026 follow-up data and payer commentary.